CL Shapiro

2.3k total citations
9 papers, 128 citations indexed

About

CL Shapiro is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, CL Shapiro has authored 9 papers receiving a total of 128 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in CL Shapiro's work include Cancer Treatment and Pharmacology (4 papers), Advanced Breast Cancer Therapies (2 papers) and Breast Cancer Treatment Studies (2 papers). CL Shapiro is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Advanced Breast Cancer Therapies (2 papers) and Breast Cancer Treatment Studies (2 papers). CL Shapiro collaborates with scholars based in United States. CL Shapiro's co-authors include Daniel F. Hayes, I. Craig Henderson, Ewa Mrózek, Kalpana Ghoshal, Jharna Datta, Sarmila Majumder, I‐Tien Yeh, E Frei, Peggy L. Porter and G. P. Canellos and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

CL Shapiro

9 papers receiving 124 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
CL Shapiro United States	5	85	58	40	30	30	9	128
Eugenia Ortega Spain	6	44 0.5×	36 0.6×	42 1.1×	25 0.8×	7 0.2×	9	114
Nawal Kassem United States	6	52 0.6×	57 1.0×	32 0.8×	17 0.6×	33 1.1×	14	115
Kai‐Keen Shiu United Kingdom	3	45 0.5×	58 1.0×	41 1.0×	9 0.3×	20 0.7×	3	95
Jeff Marks United States	6	44 0.5×	49 0.8×	60 1.5×	25 0.8×	15 0.5×	8	133
Ze-Fei Jiang China	4	82 1.0×	22 0.4×	29 0.7×	35 1.2×	22 0.7×	6	115
Bryan Johnson United States	3	90 1.1×	22 0.4×	66 1.6×	46 1.5×	6 0.2×	7	126
Nathalie Trufflandier France	5	61 0.7×	27 0.5×	21 0.5×	39 1.3×	14 0.5×	6	99
Zhenhang Meng United States	4	45 0.5×	34 0.6×	85 2.1×	10 0.3×	14 0.5×	4	125
Andrew Mant Australia	7	88 1.0×	27 0.5×	43 1.1×	32 1.1×	8 0.3×	16	130
D-M. Zahm Germany	5	61 0.7×	70 1.2×	11 0.3×	17 0.6×	10 0.3×	9	90

Countries citing papers authored by CL Shapiro

Since Specialization

Citations

This map shows the geographic impact of CL Shapiro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by CL Shapiro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites CL Shapiro more than expected).

Fields of papers citing papers by CL Shapiro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by CL Shapiro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by CL Shapiro. The network helps show where CL Shapiro may publish in the future.

Co-authorship network of co-authors of CL Shapiro

This figure shows the co-authorship network connecting the top 25 collaborators of CL Shapiro. A scholar is included among the top collaborators of CL Shapiro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with CL Shapiro. CL Shapiro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Chiuzan, Codruța, Amy Tiersten, CL Shapiro, et al.. (2017). Abstract OT1-01-10: Multi-center phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in unresectable or metastatic breast cancer. Cancer Research. 77(4_Supplement). OT1–1. 1 indexed citations

Viswanathan, Sowmya, Robert Wesolowski, Rachel M. Layman, et al.. (2011). A phase I dose-escalation study of ABT-888 (veliparib) in combination with carboplatin in HER2-negative metastatic breast cancer (MBC).. Journal of Clinical Oncology. 29(15_suppl). TPS106–TPS106. 3 indexed citations

Lustberg, Maryam B., Priya Balasubramanian, Brandon Miller, et al.. (2011). EpCAM-negative cancer–associated circulating cells (CACS) in blood samples of women with triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 29(15_suppl). e11559–e11559. 2 indexed citations

Majumder, Sarmila, et al.. (2009). MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27(kip1).. Cancer Research. 69(2_Supplement). 3023–3023. 20 indexed citations

Mrózek, Ewa, et al.. (2009). Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant.. Cancer Research. 69(2_Supplement). 6131–6131. 28 indexed citations

Perez, Alejandra, Heather Shaw, CL Shapiro, et al.. (2008). A phase I trial of scutellaria barbata (BZL101) for metastatic breast cancer. Journal of Clinical Oncology. 26(15_suppl). 1099–1099. 2 indexed citations

Porter, Peggy L., William E. Barlow, I‐Tien Yeh, et al.. (2005). Prognostic value of cell cycle regulators p27 and cyclin E: Tissue microarray analysis of 1753 women enrolled in SWOG breast cancer trial 9313. Journal of Clinical Oncology. 23(16_suppl). 507–507. 5 indexed citations

Hayes, Daniel F., I. Craig Henderson, & CL Shapiro. (1995). Treatment of metastatic breast cancer: present and future prospects.. PubMed. 22(2 Suppl 5). 5–19; discussion 19. 57 indexed citations

Shapiro, CL, R. S. Gelman, Daniel F. Hayes, et al.. (1993). Comparison of Adjuvant Chemotherapy With Methotrexate and Fluorouracil With and Without Cyclophosphamide in Breast Cancer Patients With One to Three Positive Axillary Lymph Nodes. JNCI Journal of the National Cancer Institute. 85(10). 812–817. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact